Clinical trials: Donor Lymphocyte Infusion
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies
This phase 1 trial studies the side effects and the best dose of donor CD8+ memory T-cells in treating patients with hematolymphoid malignancies.
- Conditions
- Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Trial name
- NCT01523223
- Testing
- therapeutic allogeneic lymphocytes
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Robert Lowsky
Myeloma
Trial of ID-Specific Donor Vaccinated Lymphocyte Infusion for Patients With Myeloma Relapsing or Failing to Achieve a Complete Remission After an Allogenic Transplant
The goal of this clinical research study is to learn if vaccinating a donor with your purified myeloma protein and then injecting it back into you will help your immune system control the multiple myeloma.
- Trial name
- NCT01174082
- Testing
- KLH Vaccine, KLH-id Vaccine, GM-CSF
- Where
- United States
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute
Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation
The stud will evaluate whether infusions of CD45RA-depleted lymphocytes from the donor early post-transplant is a safe way to improve immunity to common infections in recipients of TCR-alpha/beta depleted hematopoietic stem cell…
- Conditions
- Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute, Immune Deficiency Disease, Bone Marrow Failure Syndromes
- Trial name
- 45RA_NEG_DLI (NCT02337595)
- Testing
- CD45RA-depleted peripheral blood mononuclear cells
- Where
- Russia
- Volunteers
- 30 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Acute Leukemia, Acute Myeloid Leukemia
A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies
There is no curative therapy once acute leukemia patients relapse after transplant. Patients who develop clinically significant graft versus host disease (GVHD) have a lower rate of relapse than those who do not develop GVHD.
- Conditions
- Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Biphenotypic Leukemia
- Trial name
- NCT01036009
- Testing
- Withdrawal of immunosuppression and donor lymphocyte infusion
- Where
- 2 sites in United States
- Volunteers
- 43 people
- Sponsor
- University of California, San Francisco
Acute Lymphocytic Leukemia
Allo CART-19 Protocol
The primary objective is to determine the safety and survival of the redirected allogeneic T cells transduced with the anti-CD19 lentiviral vector (referred to as CART-19 cells).
- Trial name
- NCT01551043
- Testing
- CART-19
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- University of Pennsylvania
Myelodysplastic Syndromes, Myeloid Leukemia
IFN-γ to Treat Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) That Has Relapsed After Allogeneic Hematopoietic Stem Cell Transplantation
This study proposes a safe dosing regimen IFN-γ that is sufficient to stimulate IFN-γ receptors on malignant blasts in patients who developed relapsed acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) after alloSCT…
- Conditions
- Myelodysplastic Syndromes, Myeloid Leukemia, Allogeneic Stem Cell Transplantation
- Trial name
- NCT04628338
- Testing
- IFN-γ (interferon gamma-1b) injection
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Sawa Ito, MD
Donor Lymphocyte Infusion, Allogeneic Hematopoietic Stem Cell Transplantation
Chemotherapy and DLI for Prevention of Second Relapse in Patients With Relapsed Acute Leukemia After Allotransplant
Patients with acute leukemia relapsing after allotransplant and who respond to anti-leukaemia interventions are at high-risk of a second relapse.
- Conditions
- Donor Lymphocyte Infusion, Allogeneic Hematopoietic Stem Cell Transplantation, Acute Leukemia, Minimal Residual Disease
- Trial name
- NCT03297528
- Testing
- donor lymphocyte infusion
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Peking University People's Hospital
Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
Guadecitabine and Donor Lymphocyte Infusion in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Relapsing After Allogeneic Stem Cell Transplant
This phase IIa trial studies how well guadecitabine works in treating patients with acute myelogenous leukemia and myelodysplastic syndrome that has returned after a period of improvement after allogeneic stem cell transplant.
- Conditions
- Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia
- Trial name
- NCT02684162
- Testing
- Donor Lymphocytes, Guadecitabine, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 55 people
- Sponsor
- M.D. Anderson Cancer Center
Hematological Malignancy
Suicide Gene Therapy for Donor Lymphocytes Infusion After Allogeneic Hematopoietic Stem Cell Transplantation
The main complications of allogeneic hematopoietic stem cell transplantation (HSCT) include graft-versus-host disease (GVHD) and poor immune reconstitution leading to severe infections and leukemia relapse.
- Trial name
- ILD-TK01 (NCT01086735)
- Testing
- donor lymphocyte infusion
- Where
- France
- Volunteers
- 11 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Renal Cell Carcinoma, Graft-Versus-Host Disease
Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer
Background: Low-dose chemotherapy is easier for the body to tolerate than typical high-dose chemotherapy and involves a shorter period of complete immune suppression.
- Conditions
- Renal Cell Carcinoma, Graft-Versus-Host Disease, Engraftment Syndrome
- Trial name
- NCT00923845
- Testing
- Pentostatin, Sirolimus, Cyclophosphamide
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- National Cancer Institute (NCI)
Hemophagocytic Lymphohistiocytosis, X-Linked Lymphoproliferative Disorders
Stem Cell Transplant for Immunologic or Histiocytic Disorders
This study tests the clinical outcomes of a preparative regimen of fludarabine (FLU), anti-thymocyte globulin (ATG)/or Campath, and melphalan; followed by hematopoietic stem cell transplant, and a post transplant regimen of…
- Conditions
- Hemophagocytic Lymphohistiocytosis, X-Linked Lymphoproliferative Disorders, Chediak-Higashi Syndrome, Griscelli Syndrome
- Trial name
- NCT00176865
- Testing
- Stem Cell Transplant, Fludarabine, Melphalan
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Leukemia, Lymphoma
Chemotherapy Plus Donor White Blood Cell Infusion in Treating Patients With Relapsed Hematologic Cancer Following Donor Peripheral Stem Cell Transplantation
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. White blood cells from donors may be able to prevent graft-versus-host disease in patients with hematologic…
- Conditions
- Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
- Trial name
- NCT00005946
- Testing
- filgrastim, therapeutic allogeneic lymphocytes, cyclophosphamide
- Where
- United States
- Sponsor
- University of Maryland, Baltimore
Acute Myeloid Leukemia, Allogeneic Stem Cell Transplantation
A Study of Siremadlin Alone and in Combination With Donor Lymphocyte Infusion in Acute Myeloid Leukemia Post-allogeneic Stem Cell Transplant
The purpose of this study was to confirm a safe dose and schedule as well as the preliminary efficacy of siremadlin alone, and in combination with donor lymphocyte infusion (DLI), in adult participants with Acute Myeloid Leukemia…
- Trial name
- NCT05447663
- Testing
- Siremadlin
- Where
- 6 sites in Germany, Italy and 1 more
- Volunteers
- 8 people
- Sponsor
- Novartis Pharmaceuticals
Cytomegalovirus Infections
Trial of CMV Specific DLIs From 3-6/6 HLA Matched Family Member Following Nonmyeloablative Allo SCT
Human cytomegalovirus (CMV) is a benign infectious agent in the normal host, but in immunocompromised individuals, such as recipients of stem cell transplants, this virus is a major cause of morbidity and mortality.
- Trial name
- NCT01274377
- Testing
- CMV Specific T Cell donor lymphocyte infusion
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Nelson Chao
Cervical Cancer, Vaginal Cancer
Peripheral Stem Cell Transplant, White Blood Cell Infusions, Chemotherapy, and Radiation Therapy in Treating Patients With Recurrent Metastatic Cervical or Vaginal Cancer
RATIONALE: Giving low doses of chemotherapy, such as fludarabine, and radiation therapy before a donor peripheral blood stem cell transplant helps stop the growth of cancer cells.
- Trial name
- NCT00005941
- Testing
- therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate
- Where
- United States
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma
NK DLI in Patients After Human Leukocyte Antigen (HLA)-Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)
This is a phase I/II study of highly selected donor lymphocyte infusions in patients undergoing HLA-haploidentical hemopoietic stem cell transplantation. Patients will be offered "pre-emptive" NK-DLI early after HSCT.
- Conditions
- Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic Syndromes, Lymphoma
- Trial name
- NCT01386619
- Testing
- CD3-depleted/CD56+ selected natural killer cells collected from apheresis products
- Where
- 2 sites in Germany, Switzerland
- Volunteers
- 15 people
- Sponsor
- University Hospital, Basel, Switzerland
Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia
Trial of Donor Lymphocyte Infusion (DLI) and Activated DLI Following Relapse After Allogeneic Stem Cell Transplant
This study is for patients with relapsed of disease after allogeneic bone marrow The donor's T cells are activated by exposure to 2 compounds or antibodies that bind (or stick to) two compounds on T cells called CD3 and CD28.
- Conditions
- Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00674427
- Testing
- CD3/CD28 Activated T cells
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Pennsylvania
Allogeneic Stem Cell Transplant Candidate, Acute Myeloid/Lymphoblastic Leukemia
Preemptive Infusion of Donor Lymphocytes Depleted of TCR + T Cells + CD19+ B Cells Following ASCT
The purpose of this study is to reduce the risk of cancer relapse by giving a donor lymphocyte infusion (DLI) to boost the immune system early after a stem cell transplant so that leukemia cells that escaped chemotherapy can be…
- Conditions
- Allogeneic Stem Cell Transplant Candidate, Acute Myeloid/Lymphoblastic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
- Trial name
- NCT03939585
- Testing
- Cellular therapy product
- Where
- United States
- Sponsor
- Leland Metheny
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Adult Acute Lymphoblastic Leukemia
Donor Lymphocyte Infusion in Treating Patients With Persistent, Relapsed, or Progressing Cancer After Donor Hematopoietic Cell Transplant
This phase I/II trial studies the side effects of donor lymphocyte infusion and to see how well it works in treating patients with persistent, relapsed (disease that has returned), or progressing cancer after donor hematopoietic…
- Conditions
- Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Hodgkin Lymphoma
- Trial name
- NCT00068718
- Testing
- Therapeutic Allogeneic Lymphocytes
- Where
- 4 sites in United States, Germany and 1 more
- Volunteers
- 35 people
- Sponsor
- Fred Hutchinson Cancer Center
Leukemia, Lymphoma
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
The goal of this clinical research study is to learn what dose of a kind of immune cell called T-lymphocytes (T-cells) given as a donor infusion about 8-9 weeks after a stem cell transplant has the best results.
- Conditions
- Leukemia, Lymphoma, Myeloma, Myeloproliferative Diseases
- Trial name
- NCT01518153
- Testing
- Fludarabine, Melphalan, Alemtuzumab
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center